Clinical trials: Juvenile Arthritis
- Condition Juvenile Arthritis
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Juvenile Idiopathic Arthritis
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
- Trial name
- NCT01500551
- Testing
- Tofacitinib
- Where
- 104 sites in United States, Argentina and 17 more
- Volunteers
- 302 people
- Sponsor
- Pfizer
Juvenile Idiopathic Arthritis, JIA
Juvenile Idiopathic Arthritis (JIA) Registry
This is a global registry, to evaluate the long-term safety of Humira® in patients with moderate to severe polyarticular Juvenile Idiopathic Arthritis (JIA), that are treated as recommended in the Humira® product label.
- Trial name
- STRIVE (NCT00783510)
- Testing
- adalimumab, Methotrexate
- Where
- 92 sites in United States, Australia and 15 more
- Volunteers
- 849 people
- Sponsor
- AbbVie
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis…
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus
- Trial name
- EMERALD (NCT05001737)
- Testing
- Emapalumab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 33 people
- Sponsor
- Swedish Orphan Biovitrum
Polyarticular Course Juvenile Idiopathic Arthritis
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
This is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 18 weeks.
- Trial name
- GALAHOPPER (NCT07554495)
- Testing
- Filgotinib
- Where
- 14 sites in Belgium, Czechia and 7 more
- Volunteers
- 65 people
- Sponsor
- Alfasigma S.p.A.
Juvenile Psoriatic Arthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06100744
- Testing
- Adalimumab, Risankizumab
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Juvenile Idiopathic Arthritis
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to…
- Trial name
- NCT01230827
- Testing
- CNTO 148 (Golimumab), Methotrexate
- Where
- 35 sites in United States, Austria and 10 more
- Volunteers
- 173 people
- Sponsor
- Janssen Research & Development, LLC
Juvenile Idiopathic Arthritis
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis
This open-label, multicenter study will evaluate the pharmacokinetics, pharmacodynamics, and safety of subcutaneously administered tocilizumab in participants with Systemic Juvenile Idiopathic Arthritis (sJIA).
- Trial name
- NCT01904292
- Testing
- Tocilizumab
- Where
- 42 sites in United States, Argentina and 10 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)
This study is designed to analyze the frequency and incidence rate of pulmonary complications in JIA participants who received biological DMARDs and non-biologic DMARDs.
- Trial name
- NCT02784808
- Testing
- Biological DMARDs, Non-Biologic DMARDs
- Volunteers
- 4,557 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
The primary objective of this Phase 4, multi-center, open-label study is to evaluate the safety and tolerability of DUEXIS in Juvenile Idiopathic Arthritis (JIA) patients aged 10 years to 16 years, 11 months, treated up to 24…
- Trial name
- NCT01563185
- Testing
- 800 mg ibuprofen/26.6 mg famotidine
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Amgen
Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
A study to demonstrate efficacy and safety of anakinra in pediatric and adult Japanese patients with Still's disease (Systemic juvenile idiopathic arthritis [SJIA] and Adult-onset Still's disease [AOSD]).
- Trial name
- NCT05814159
- Testing
- Anakinra
- Where
- 8 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Swedish Orphan Biovitrum
Juvenile Idiopathic Arthritis (JIA)
OLE Study With Filgotinib in JIA
This OLE study is designed to evaluate long-term safety, tolerability, and efficacy of filgotinib in patients with polyarticular or systemic juvenile idiopathic arthritis (pJIA-sJIA) who have completed the treatment…
- Trial name
- OLE JIA (NCT07553182)
- Testing
- Filgotinib
- Where
- 4 sites in France, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- Alfasigma S.p.A.
Arthritis, Juvenile Idiopathic
Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
This is a multicenter, Phase 3 randomized, placebo-controlled study designed to evaluate adalimumab in children 4 to 17 years old with polyarticular juvenile idiopathic arthritis (JIA) who are either methotrexate (MTX) treated or…
- Trial name
- NCT00048542
- Testing
- OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 171 people
- Sponsor
- Abbott
Rheumatoid Arthritis, Juvenile
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid Arthritis
The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Juvenile Rheumatoid Arthritis (JRA).
- Trial name
- NCT00036374
- Testing
- Infliximab
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Arthritis, Juvenile
A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of golimumab administered intravenously (IV) to pediatric participants with…
- Trial name
- GO-VIVA (NCT02277444)
- Testing
- Golimumab, Methotrexate
- Where
- 38 sites in United States, Argentina and 7 more
- Volunteers
- 130 people
- Sponsor
- Janssen Research & Development, LLC
Juvenile Idiopathic Arthritis
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
This open-label extension of the JIGSAW studies (WA28117 [NCT01904279] and WA28118 [NCT01904292]) is designed to evaluate the long-term safety and efficacy of subcutaneous (SC) tocilizumab treatment in participants with…
- Trial name
- NCT02165345
- Testing
- Tocilizumab
- Where
- 31 sites in United States, Argentina and 10 more
- Volunteers
- 82 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis
Primary Objective of the study: the purpose of this extension study was to determine the safety of Givinostat in a long term treatment of patients who participated in DSC/08/2357/36 study with good results (clinical benefit at…
- Trial name
- NCT01557452
- Testing
- Givinostat
- Where
- Czechia
- Volunteers
- 1 people
- Sponsor
- Italfarmaco
Juvenile Rheumatoid Arthritis
BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept).
- Trial name
- NCT00095173
- Testing
- Abatacept
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 214 people
- Sponsor
- Bristol-Myers Squibb
Arthritis, Juvenile Rheumatoid
A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA
To study Celebrex versus naproxen to see if it decreases symptoms of juvenile arthritis such as pain and swelling.
- Trial name
- NCT00652925
- Testing
- Celecoxib, Naproxen
- Where
- 58 sites in United States, Belgium and 13 more
- Volunteers
- 225 people
- Sponsor
- Pfizer
Still's Disease, Including SJIA and AOSD, With MAS or ILD Complications
Managed Access Programs for MAS825, Arumakimig
The purpose of this registration is to list Managed Access Programs (MAPs) related to MAS825, arumakimig
- Trial name
- NCT07889310
- Testing
- Arumakimig
- Sponsor
- Novartis Pharmaceuticals
Polyarticular Juvenile Idiopathic Arthritis
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
This is an open-label, extension, Phase III study to evaluate the long-term safety, efficacy and PK of MRA in patients with pJIA who participated in Study MRA318JP.
- Trial name
- NCT00144625
- Testing
- MRA(Tocilizumab)
- Volunteers
- 19 people
- Sponsor
- Chugai Pharmaceutical